U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
